← All trials
NCT05608928
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2022
- Primary completion
- May 30, 2023
- Completion date
- Jun 30, 2023
- First posted
- Nov 8, 2022
- Last posted
- Nov 8, 2022
- Enrollment
- 76
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tropical Gastroenterology & Nutrition Group (TROPGAN)Lead sponsor
- Institut PasteurOverall official - principal investigator
- Aga Khan UniversityOverall official - principal investigator
- International Center for Diarrheal Disease ResearchOverall official - principal investigator
- Bill and Melinda Gates FoundationCollaborator
- Tropical Gastroenterology & Nutrition Group (TROPGAN)Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.